Entrada Therapeutics has secured authorisation from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) to ...

Indicated for patients with a confirmed mutation of the dystrophin gene amenable to exon 51 skipping, the drug could be used in around 13% of the disease population. Sarepta’s share price almost ...

Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) ("Satellos" or the "Company"), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle ...

Equities researchers at Zacks Research lifted their Q4 2024 earnings estimates for Sarepta Therapeutics in a research note issued to investors on Monday, February 3rd. Zacks Research analyst S.

Lead drug PGN-EDO51 targets a mutation in the dystrophin gene that can be treated by skipping exon 51, making it a potential rival to Sarepta Pharma's Exondys 51 (eteplirsen), which made $454 ...

DMD is a genetic disorder in which the body is unable to make dystrophin, a protein that normally helps to protect muscles from damage. This leads to progressive damage to skeletal muscles, which move ...

The Lunar New Year has always been a time of reflection and renewal for me. This year, though, it was bittersweet because my longtime caregiver plans to return to her home country in a few weeks. With ...

After hours: February 7 at 7:48:33 PM EST Loading Chart for SRPT ...

After hours: 6 February at 5:49:33 pm GMT-5 ...